Afya Limited (NASDAQ:AFYA - Get Free Report) VP Lelio De Souza Junior sold 16,279 shares of the business's stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $14.53, for a total transaction of $236,533.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Lelio De Souza Junior also recently made the following trade(s):
- On Tuesday, April 7th, Lelio De Souza Junior sold 26,753 shares of Afya stock. The shares were sold at an average price of $14.95, for a total transaction of $399,957.35.
Afya Price Performance
Shares of AFYA traded down $0.16 during mid-day trading on Friday, hitting $15.07. 110,572 shares of the company traded hands, compared to its average volume of 118,058. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of 10.32, a PEG ratio of 0.67 and a beta of 0.48. The business has a 50-day moving average of $14.48 and a 200 day moving average of $14.70. Afya Limited has a one year low of $13.00 and a one year high of $19.90.
Afya (NASDAQ:AFYA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.05. The firm had revenue of $147.08 million during the quarter, compared to analysts' expectations of $174.74 million. Afya had a net margin of 20.31% and a return on equity of 18.77%. As a group, equities analysts expect that Afya Limited will post 1.52 earnings per share for the current fiscal year.
Afya Announces Dividend
The company also recently declared an annual dividend, which was paid on Monday, April 6th. Stockholders of record on Wednesday, March 25th were paid a dividend of $0.656 per share. This represents a dividend yield of 433.0%. The ex-dividend date of this dividend was Wednesday, March 25th. Afya's dividend payout ratio is 45.21%.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Sanford C. Bernstein upgraded Afya to a "market perform" rating in a research report on Friday, January 16th. Zacks Research raised shares of Afya from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. UBS Group reiterated a "neutral" rating and set a $16.00 price target (down from $18.00) on shares of Afya in a research report on Friday, January 16th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $22.00 price target (down from $24.50) on shares of Afya in a research note on Wednesday, January 7th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Afya in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $17.30.
Read Our Latest Analysis on Afya
Institutional Trading of Afya
Hedge funds have recently bought and sold shares of the stock. Doma Perpetual Capital Management LLC boosted its holdings in shares of Afya by 50.6% in the third quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company's stock valued at $13,910,000 after buying an additional 299,419 shares during the period. SPX Gestao de Recursos Ltda acquired a new stake in shares of Afya during the third quarter worth $2,895,000. Swedbank AB lifted its position in Afya by 170.3% in the 4th quarter. Swedbank AB now owns 189,200 shares of the company's stock valued at $2,916,000 after acquiring an additional 119,200 shares in the last quarter. Jump Financial LLC bought a new stake in Afya in the 2nd quarter valued at $731,000. Finally, Qube Research & Technologies Ltd acquired a new position in Afya in the 3rd quarter worth $610,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.
About Afya
(
Get Free Report)
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya's offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Afya, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Afya wasn't on the list.
While Afya currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.